Pamidronate in the treatment of bone metastases: Results of 2 dose-ranging trials in patients with breast or prostate cancer

Allan Lipton, D. Glover, Harold Harvey, S. Grabelsky, K. Zelenakas, R. Macerata, J. Seaman

Research output: Contribution to journalArticlepeer-review

65 Scopus citations

Abstract

Four intravenous regimens of pamidronate (Aredia®) were evaluated for palliative treatment of bone metastases in 2 randomized open-label trials in patients with breast cancer (n = 61) or prostate cancer (n = 58). In breast cancer patients, administration of pamidronate 60 mg every 4 weeks, 60 mg every 2 weeks, or 90 mg every 4 weeks for 3 months resulted in statistically and clinically significant reductions in bone pain, with accompanying decreases in biochemical markers of bone turnover; a regimen of 30 mg every 2 weeks was not effective. Healing of bone lesions was observed in 25% of breast cancer patients. In prostate cancer patients, the same regimens of pamidronate produced reductions in bone pain, but no dose-response relationship was apparent. Moreover, there were no consistent changes in biochemical indices in these patients, and no healing of bone lesions occurred. The different response to pamidronate in those 2 patient populations may reflect the different severity of metastatic disease at baseline. Side effects of pamidronate were mild and transient in both studies.

Original languageEnglish (US)
Pages (from-to)31-35
Number of pages5
JournalAnnals of Oncology
Volume5
Issue numberSUPPL. 7
StatePublished - Jan 1 1994

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Pamidronate in the treatment of bone metastases: Results of 2 dose-ranging trials in patients with breast or prostate cancer'. Together they form a unique fingerprint.

Cite this